🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

13 results for “moxifloxacin” Clear

  1. MOXIFLOXACIN, CLOFAZIMINE, PRETOMANID, LINEZOLID, BEDAQUILINE

    Pari Pharma GmbH

    Patients diagnosed at the study sites with rifampicinresistant tuberculosis during the recruitment period will be evaluated for study inclusion.

    phase 3 small molecule active

    1 trial

  2. Moxifloxacin

    Pfizer

    Chronic Bronchitis

    phase 3 small molecule completed

    1 trial

  3. Moxifloxacin

    United Therapeutics Europe Ltd

    Chronic Obstructive Pulmonary Disease (COPD).

    phase 3 small molecule active

    1 trial

  4. Moxifloxacin

    BRIGHT MINDS BIOSCIENCES INC.

    Tuberculosis, Pulmonary, Drug Sensitive

    phase 3 small molecule completed

    1 trial

  5. Moxifloxacin, Ethambutol, Isoniazid, Pyrazinamide & Rifampicin

    BRIGHT MINDS BIOSCIENCES INC.

    Pulmonary Tuberculosis

    phase 3 small molecule completed

    1 trial

  6. TOCILIZUMAB, MOXIFLOXACIN, CLARITHROMYCIN, ERYTHROMYCIN LACTOBIONATE, PIPERACILLIN AND BETA-LACTAMASE INHIBITOR , CEFTRIAXONE, BARICITINIB, HYDROCORTISONE, DEXAMETHASONE, ROXITHROMYCIN, LEVOFLOXACIN, BALOXAVIR MARBOXIL, AZITHROMYCIN, AMOXICILLIN AND BETA-LACTAMASE INHIBITOR , AZITHROMYCIN, IMATINIB, OSELTAMIVIR, CLARITHROMYCIN, DEXAMETHASONE, ERYTHROMYCIN

    Disc Medicine

    Respiratory tract infection

    phase 3 small molecule active

    1 trial

  7. Moxifloxacin (M)

    BRIGHT MINDS BIOSCIENCES INC.

    Pulmonary Tuberculosis

    phase 2 small molecule completed

    1 trial

  8. Moxifloxacin (with rifampin, pyrazinamide, and ethambutol)

    BRIGHT MINDS BIOSCIENCES INC.

    Tuberculosis

    phase 2 small molecule completed

    1 trial

  9. Rimactan 300 mg hörð hylki., Moxifloxacin Tillomed 400 mg film coated tablets, LINEZOLID, RIMSTAR®, COMPRIMIDOS RECUBIERTOS CON PELÍCULA, Hidroxil B1-B6-B12 comprimidos recubiertos con película, Zyvoxid 600 mg Filmtabletten

    The George Institute

    Bacilliferous pulmonary tuberculosis

    phase 2 small molecule active

    1 trial

  10. Placebo spray and oral moxifloxacin placebo

    Jazz Pharmaceuticals Ireland Limited

    Effects of Sativex on ECG

    phase 1 small molecule completed

    1 trial

  11. Telaprevir; Moxifloxacin; Placebo

    Vertex Pharmaceuticals (Australia) Pty.

    Hepatitis C

    phase 1 small molecule completed

    1 trial

  12. AMPICILLIN , AMOXICILLIN AND BETA-LACTAMASE INHIBITOR , OFLOXACIN , MOXIFLOXACIN , AZITHROMYCIN , LEVOFLOXACIN , AMOXICILLIN , PRISTINAMYCIN , ERYTHROMYCIN , CIPROFLOXACIN , CLARITHROMYCIN

    Pari Pharma GmbH

    Community acquired pneumonia (CAP)

    approved small molecule active

    1 trial

  13. moxifloxacin

    Hospital Authority, Hong Kong

    Intra-abdominal Infection

    approved small molecule completed

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources